Compare Moderna, Inc. (MRNA) vs Nerdwallet Inc (NRDS) Price & Performance

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

NerdWallet (NRDS) trades at $9.48, down 3.27% today, amid mixed signals. The stock shows bullish technical momentum with a 10.87 P/E ratio indicating potential undervaluation. Revenue grew to $836.6M in 2025, with net income reaching $48.7M, though Q2 2026 earnings missed expectations. Positive analyst sentiment includes a 66.66% buy rating, with news highlighting a 27.9% upside potential from Zacks Investment Research on August 10, 2026.

Outlook is cautiously optimistic with strong profitability margins and cash flow growth, but risks include organic-search pressure and competitive threats. The stock's valuation and recent momentum suggest upside, though investors must monitor earnings consistency and market volatility.